Benzoquinone ansamycins

Details Benzoquinone ansamycins Benzoquinone ansamycins

2005-03-29

2005-03-29

Kifle, Bruck (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C540S461000

Reexamination Certificate

active

06872715

ABSTRACT:
The invention relates to benzoquinone ansamycin analogs useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. Therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are useful to treat cancer and non-cancerous disease conditions.

REFERENCES:
patent: 3595955 (1971-07-01), De Boer et al.
patent: 3987035 (1976-10-01), Rinehart, Jr. et al.
patent: 4075339 (1978-02-01), Rinehart, Jr. et al.
patent: 4261989 (1981-04-01), Sasaki et al.
patent: 4421687 (1983-12-01), Hasegawa et al.
patent: 4421688 (1983-12-01), Muroi et al.
patent: 4540517 (1985-09-01), Tanida et al.
patent: 5387584 (1995-02-01), Schnur
patent: 5932566 (1999-08-01), Schnur et al.
patent: 5968921 (1999-10-01), Gold
patent: 6245759 (2001-06-01), Bilodeau et al.
patent: 6306874 (2001-10-01), Fraley et al.
patent: 6313138 (2001-11-01), Fraley et al.
patent: 20020045570 (2002-04-01), Rosen et al.
patent: 55-111419 (1980-08-01), None
patent: 55-111470 (1980-08-01), None
patent: 56-100766 (1981-08-01), None
patent: 57-163369 (1982-10-01), None
patent: 63-218620 (1988-09-01), None
patent: 4-46120 (1992-02-01), None
patent: WO 9314215 (1993-07-01), None
patent: WO 9851702 (1998-11-01), None
patent: WO 0003737 (2000-01-01), None
patent: WO 0037050 (2000-06-01), None
patent: WO 0126693 (2001-04-01), None
patent: WO 0236574 (2002-05-01), None
patent: WO 02079167 (2002-10-01), None
patent: WO 02087497 (2002-11-01), None
patent: WO 03026571 (2003-04-01), None
patent: WO 03050295 (2003-06-01), None
patent: WO 03066005 (2003-08-01), None
Citri et al., EMBO Journal (2002) 21:2407-2417.
Münster et al., Clinical Cancer Research (2001) 7:2228-2236.
Kamal, A. et al. (2003). “A High-Affinity Conformation of Hsp90 Confers Tumour Selectivity on Hsp90 Inhibitors,”Nature425:407-410.
Neckers, L. and Lee, Y-S. (2003). “The Rules of Attraction,”Nature425:357,359.
International Search Report mailed on Nov. 28, 2003 for PCT application No. PCT/US02/24891 filed Aug. 5, 2002, 4 pages.
Schnur, R. G. et al. (1995). “erbB-2Oncogene Inhibtion by Geldanamycin Derivatives: Synthesis, Mechanism of Action, and Structure-Activity Relationships,”J. Med. Chem. 38:3813-3820.
Schnur, R. C. et al., (1995). “Inhibition of the Oncogene Product p185erbB−2in Vitro and in Vivo by Geldanamycin and Dihydrogeldanamycin Derivatives,”J. Med. Chem. 38:3806-3812.

Affiliated with

Also associated with

Rating

Benzoquinone ansamycins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Benzoquinone ansamycins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzoquinone ansamycins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3437108